Brand Name
Naprosyn
Broad Category
Analgesic / Antipyretic / NSAID
Pharm class
Propionic acid derivative / Nonselective NSAID
MOA
Nonselective COX inhibition preventing the substrate arachidonic acid from binding to the active site, thus blocking synthesis of prostaglandins
Indications
Pain / Inflamation
Fever
decrease opioid requirements perioperative
PO dosing
250 - 500 mg
GI effects
Gastropathy
GI bleeding
Renal effects
sodium water retention
Reversible impairment of GFR
Hematologic effects
increased bleeding due to inhibition of thromboxane synthesis
Contraindications
Asthma / Samters triad
Hypersensitivity
Gestation after 30 weeks (premature PDA closure)
GI ulcer / hemorrhage
Precautions or avoidance
Renal / Hepatic disease
Orthopdeics (inhibit bone formation)
Drug - Drug interactions
Albumin-bound drugs:
- competitively displace albumin-bound drugs (warfarin, phenytoin, valproic acid) increasing risk for toxicity)
Decreases renal clearance of lithium and digoxin
Increases risk of ulcers with: corticosteroids and ASA
Metabolism
Hepatic
- CYP2C9 (primarily)
- glucuronidation
Elimination
Renal
Vd Considerations
Small
- hydrophilic
- remains in plasma / ECF
- highly protein bound
Clearance Considerations
Reduced clearance with
- renal dysfunction
- hepatic impairment
- elderly patients
Protein binding
Very high (99%)
Albumin